The Motley Fool

One 5% yielder I’d consider over GlaxoSmithKline plc

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Screen of various price trends, possibly in FTSE 100
Image source: Getty Images.

FTSE 100 pharmaceutical giant GlaxoSmithKline (LSE: GSK) faces a number of challenges in 2018.

With the drug maker unlikely to emerge from its earnings plateau for some time, amid growing competitive pressures in its HIV and respiratory businesses, there’s growing concern about the sustainability of its dividends.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Dividend frozen at 80p

GSK has frozen its annual dividend per share at 80p since 2015, but still it has struggled to generate enough profits and free cashflow to afford its current level of shareholder payouts. Net debt has climbed from £10.7bn at the end of 2015 to £14.2bn by the end of September 2017.

And although free cashflow has improved significantly in recent months, thanks to a positive currency benefit and the launch of new products, the company’s financial flexibility could come under pressure as it ponders the acquisition of Pfizer’s consumer health unit.

Little earnings movement

The earnings plateau is expected to continue for some time ahead, as the impact of new product launches is expected to be offset by the legacy effects of patent losses on key products like respiratory drug Advair. Although City analysts expect underlying earnings to have grown by 8% this year, they expect a 3% reversal this year. And for 2019, they think there will be a rebound in its bottom line of just 4%.

Although valuations aren’t pricey, with the shares trading at just 12.2 times expected earnings this year, the risk of a dividend cut continues to overhang its shares. As such, GSK’s current 6.1% dividend doesn’t tempt me right now.

A better pick

Instead, I reckon automotive, cycling and leisure retailer Halfords (LSE: HFD) represents a better dividend pick. In my view, the company has better fundamentals which give it a positive earnings outlook — an important criterion for dividend growth.

Halfords reported a 3.2% increase in sales over the 15 weeks to January 12, after strong trading in its cycling division. Like-for-like sales at its car maintenance division were also positive, with sales up 2.1% over the same period on improved car headlamp bulb and de-icer sales.

However, on the downside, Halfords cautioned that it expects the UK retail environment to “remain subdued” and warned that it would face higher costs because of the weaker pound. But I’m still more sanguine about its earnings prospects, due to the positive top-line picture, with growing like-for-like sales, and new store openings in the UK and in Europe.

Defensive appeal

In addition, unlike most retail stocks, Halfords is an intrinsically defensive stock. This is because car maintenance and repair, a non-cyclical business, makes up around 70% of revenues. After all, customers can’t avoid taking their cars for their annual MOT or conducting necessary repairs, due to legal requirements and the need to the keep their vehicles in good working order.

Halfords’ earnings multiples are similar to GSK’s, with shares in the retailer trading on 12.2 times expected earnings this year. And on top of this, the stock yields 5.1%

One Killer Stock For The Cybersecurity Surge

Cybersecurity is surging, with experts predicting that the cybersecurity market will reach US$366 billion by 2028more than double what it is today!

And with that kind of growth, this North American company stands to be the biggest winner.

Because their patented “self-repairing” technology is changing the cybersecurity landscape as we know it…

We think it has the potential to become the next famous tech success story.

In fact, we think it could become as big… or even BIGGER than Shopify.

Click here to see how you can uncover the name of this North American stock that’s taking over Silicon Valley, one device at a time…

Jack Tang has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.